enced facial paresthesias of a mild, electric-shock-like nature that were also associated with the subjective sense of facial twitching. Each episode lasted approximately 5 minutes. No involuntary facial movements were ever verified by direct observation in a mirror or by observations of others. She noticed a heightened intensity of the paresthesias in the circumoral area if she smoked a cigarette after taking her medication. She could recall no associated hyperventilation, shortness of breath, coughing spells, or preceding heightened anxiety. After the third day, these symptoms never recurred despite continuation of the medication.

Case 2. Ms. B, a 29-year-old Eurasian woman diagnosed by DSM-IV criteria with dysthymia and borderline personality traits, was placed on paroxetine 20 mg/day. On the second day of treatment, shortly after taking this medication, she experienced several paroxysms of electric-shock-like paresthesias isolated to the left side of her face and head. These came on repeatedly over a 3-minute period, with each "burst" lasting 5–10 seconds. Because these symptoms were so bothersome to the patient, she discontinued the medication permanently. No muscular symptoms, exacerbating or relieving factors, precipitating movements or actions, or other associated features were recalled. However, the irregularity and brevity of these adverse effects may have limited such identification. The patient was subsequently placed on sertraline treatment without incident.

Case 3. Ms. C, a 22-year-old Native American woman diagnosed with major depression, was placed on paroxetine 20 mg/day 2 weeks after failing a trial of sertraline 50 mg/day secondary to gastrointestinal complaints. Within minutes of taking the medication, she experienced a paroxysm of electric-shock-like paresthesias isolated to her head. They seemed unrelated to any other activity and lasted for approximately 15 seconds, remitting without residua. These symptoms recurred daily after the morning dose for the first 5 days of chemotherapy. Ms. C, however, was able to continue on paroxetine treatment and suffered no adverse effects thereafter.

Paroxetine has been noted to have several adverse effects related to the nervous system including somnolence, dizziness, insomnia, tremor, nervousness, anxiety, paresthesias, agitation, myoclonus, and confusion.1 Previously, Frost and Lal5 described three patients who experienced electric-shock-like sensations upon discontinuation of paroxetine (in two) or sertraline (in one). This was the first time paroxysmal paresthesias of an electrical character had been described associated with paroxetine. In each case, they lasted "a few seconds" or less and "travelled" or radiated from one region to another, often to the limbs. Interestingly, this description is very similar to Lhermitte's sign, "sudden 'electrical' pains occurring with neck flexion down the spine and into the upper extremities."9 Of note, one of their patients could avoid these sensations by "keeping his head motionless." Although commonly associated with multiple sclerosis, Lhermitte's sign has been associated with over a dozen spinal cord disorders, but never with transient drug effects.1

By contrast, our patients represent the first cases described of paroxysmal, shock-like paresthesias associated with the initiation of paroxetine. Although each of the paroxysms of paresthesias was short-lived as in the previous cases, lasting 5 seconds to 5 minutes, all were isolated to the head or face and did not radiate or travel. All of Frost and Lal's patients had involvement of the trunk, two also had involvement of the extremities, but only one had involvement of the face or head. All other patients with reported paroxysms have been women, whereas our patients were men (average 55 years and 27.5 years, respectively). All of our cases and two of the previous three cases had prominent anxiety features, and all patients in both groups described their paresthesias as electrical in character.

Each of our three patients reported their symptoms independently of each other over a 1.5-month period, and none knew one another. Our patients were taking no concurrent medications, their medications came from separate pharmaceutical batches, and they had no underlying medical or neurologic disorders that might have contributed to their presenting complaint. Two of the three patients had not previously received psychotropic medications. The third patient had been on sertraline therapy for 2 weeks and did not appear to be experiencing withdrawal symptoms. Although all three were nicotine dependent, only one patient reported more intensified and focused symptoms while smoking. Additionally, she was the only patient who also sensed subjective facial twitching, which may have represented fasciculations, although no objective observation occurred to confirm this.

In each of our patients, the reported paroxysmal, shock-like paresthesias had a clear proximal link to the ingestion of paroxetine during the period of medication initiation. These cases are reported in order to alert physicians who prescribe paroxetine to the possibility of this adverse effect upon its initiation. The opinions and assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the Department of the Army, Department of Defense, or the U.S. Government.

REFERENCES
5. CPT Timothy R. Bergin, D.D.S., M.D. Fort Bragg, North Carolina

Benztropine in the Treatment of Venlafaxine-Induced Sweating

Sir: Sweating is a relatively common side effect seen with serotonin selective reuptake inhibitors (SSRIs) and has been reported in 7% to 11% of patients treated with SSRIs and 12% of patients treated with venlafaxine, an antidepressant with the ability to inhibit the reuptake of serotonin and norepinephrine.1 The following case indicates that this side effect can cause severe social disruption and limit effective treatment of depression. A possible management strategy is also suggested.

Case report. Ms. A, a 48-year-old school teacher with a 4-year history of depression, was diagnosed as having major depressive episode and dysthymia, but was refractory to trials of monoamine oxidase inhibitors and tricyclic antidepressants. In April of the previous year, she noted partial improvement in her depression, but experienced "hot flashes" occurring several times a day and lasting 5

J Clin Psychiatry 58:4, April 1997
to 10 minutes. Symptoms included a feeling of heat all over her body and perspiration on the back of her neck. Follicle-stimu-
lating hormone levels were normal in this patient.

75 mg t.i.d. was accompanied by complete remission of depres-
sion, but such severe and socially embarrassing sweating that
the patient felt compelled to discontinue the drug. Ms. A was
encouraged to restart venlafaxine at 75 mg b.i.d. with benzetto-
pine added at 0.5 mg b.i.d. The "hot flashes" did not recur, and
venlafaxine was then increased to 75 mg t.i.d. with subsequent
remission of depression and no side effects.

The eccrine sweat glands are stimulated by the sympathetic
nervous system; however, the postganglionic fibers that reach
the muscarinic receptors on the end organ are cholinergic. The
preoptic and anterior hypothalamic nuclei are the areas of the
hypothalamus that contain heat sensitive and cold sensitive
neurons and are mainly responsible for the stimulation of these
sweat glands.2

The exact mechanism of antidepressant-induced sweating is
unknown. It has been reported that the use of clonidine is suc-
cessful in the treatment of tricyclic-induced sweating8 and that
propranolol increases sweating.3 These findings suggest a role
for norepinephrine in the mechanism of antidepressant-induced
sweating. Presumably SSRIs enhance sweating either indirectly
by affecting the sympathetic system or directly by acting on the
hypothalamus.

The use of the anticholinergic benztpine was effective in
preventing the excess sweating in our patient and allowed her to
continue treatment with venlafaxine. Benztpine most likely
blocked the acetylcholine receptors on the eccrine sweat glands
and thereby caused a reduction in sweating. Anticholinergic
agents for the management of excess sweating induced by SSRIs.

REFERENCES
1. Feighner JP. The role of venlafaxine in rational antidepressant therapy.
J Clin Psychiatry 1994; 55(9, suppl A):62-68
2. Guyton AC. Textbook of Medical Physiology, 8th ed. Philadelphia,
Pa: WB Saunders Company; 1991
Psychiatry 1995; 56:35
Psychiatry 1989; 50:146-147

Aaron Garber
Robert J. Gregory, M.D.
Syracuse, New York

Stereotypic Movement Disorder

Sirs: Castellanos et al.1 (March 1996 issue) recently reported
that DSM-IV stereotypic movement disorder can be diagnosed
in intellectually normal adult patients. This paper is another in a
series of fascinating studies conducted by Rapoport and col-
leagues on the differential response of unwanted repetitive behav-
iors such as hair pulling2 and nail biting2 to clomipramine and
desipramine. The idea that such behaviors fall on a
obsessive-compulsive disorder (OCD) spectrum of conditions
may provide a valuable heuristic in both clinical and research
settings.4

In their paper, Castellanos et al.1 reported the response of
three patients to both clomipramine and desipramine, two of
whom used limited doses. In two of the three subjects, there
seemed to be a better response to clomipramine than desipra-
mine. In only one of the three patients, however, was there a
significant improvement in both OCD and stereotypic
behavior.

In a small study of intellectually normal patients with stereotypic behaviors occasionally do present to our OCD Clinic. Previously, we have

described the use of fluoxetine in patients with skin picking.4 In

addition, we have recently used serotonin specific reuptake
inhibitors for other patients who would meet DSM-IV criteria for
stereotypic movement disorder.

Case 1. A 34-year-old man presented with repetitive rocking
behaviors and repetitive face picking. The patient exhibited
schizotypal and borderline personality disorder traits. He
stated that the repetitive behaviors had been present since adolescence.
On fluoxetine 20 mg/day, the patient experienced a decrease in
anxiety, which he stated allowed him to have better control over
his repetitive behaviors. These exhibited a mild to moderate im-
provement within a few weeks. The patient elected to continue
medication for over a year.

Case 2. A 48-year-old woman presented with lifelong repeti-
tive lip biting. She met DSM-IV criteria for major depression.
Previous episodes of depression had responded to fluoxetine 20
mg/day, and this regimen was again initiated. There was a
marked improvement in mood within a few weeks, but only a
minimal improvement in lip biting. Increasing the dose to 40 mg
daily had no additional effects on this behavior. The patient con-
tinued taking fluoxetine for over a year.

Case 3. A 22-year-old man presented with repetitive head
banging prior to falling asleep. This behavior consumed more
than an hour of time each night and had persisted since child-
hood. Paroxetine 20 mg/day was initiated. The patient had no
improvement in his behavior and chose not to continue the dis-
continue the medication after 4 weeks.

Case 4. A 53-year-old woman presented with repetitive
checking behaviors that met criteria for OCD. In addition, she
complained of repetitive rubbing of her nose. She stated that
this was simply a habit, rather than a compulsion that she did
to get rid of intrusive thoughts. Both OCD and nose rubbing had
been present since childhood. The patient was treated with citalopram
at doses of up to 60 mg/day. There was minimal improvement in
OCD symptoms over 3 months and no change in nose rubbing.

Case 5. A 32-year-old woman presented with symptoms of
hair pulling since age 10. She met DSM-IV criteria for trichotil-
omania. The patient noted that when she was unable to pull
da hair, for example, in public situations, she would then rock
back and forth repetitively. The patient was treated with citalopram
up to 40 mg/day. Within a few weeks of medication, there was
improvement in both hair pulling and rocking, but over time
both symptoms returned.

Case 6. A 30-year-old man presented with complaints of ex-
cessive nose picking of about 6 years in duration. The patient
was ashamed of this behavior, which he felt unable to control.
Citalopram 20 mg/day was initiated. After 4 weeks of treatment,
the patient reported minimal improvement in his behavior.
However, in view of difficulty with ejaculation on the medica-
tion, he elected to discontinue treatment.

Case 7. A 28-year-old man presented with contamination
fears and excessive hand washing that met DSM-IV criteria for
OCD. The patient also gave a history of rhythmic shaking of
the right foot, which he described as leading to a reduction of
tension. There was no response of symptoms to dothiepin
150 mg/day for 6 weeks or to clomipramine 150 mg/day for 8
weeks. However, on fluoxetine 60 mg/day, there was marked
improvement in both OCD and foot shaking over the course of
16 weeks.

J Clin Psychiatry 58:4, April 1997